依达拉奉对急性脑梗死患者血清基质金属蛋白酶9表达的影响(1)
 |
| 第1页 |
参见附件(1907KB，2页)。
[摘要]目的观察分析依达拉奉治疗急性脑梗死的疗效以及对急性脑梗死患者血清基质金属蛋白酶9(MMP-9)表达的影响。方法100例急性脑梗死患者根据入院先后顺序随机分为治疗组(常规治疗+依达拉奉)和对照组(常规治疗)各50例，比较两组的疗效及MMP-9的变化情况。结果治疗组的总有效率高于对照组，两组神经功能缺损评分均降低，治疗组神经功能缺损评分降低明显，两组MMP-9的含量均明显降低，治疗组的MMP-9明显低于对照组(P<0.05)。结论依达拉奉治疗急性脑梗死疗效明显，可以降低MMP-9的水平，值得临床予以重视。
[关键词]急性脑梗死；依达拉奉；基质金属蛋白酶9(MMP-9)；影响
[中图分类号] R743.3 [文献标识码]B[文章编号] 1673-9701(2011)27-70-02
The Impact of Edaravone on Acute Cerebral Infarction and Its Serum Matrix Metalloproteinase-9’s Expression
SHENWeijunJIANG Huanxin LIAO Songming
Guangzhou Baiyun District People's Hospital，Guangzhou 510500，China
[Abstract] Objective To observe and analyze the edaravone treatment acute cerebral infarction and the impact on serum matrix metalloproteinase 9(MMP-9)’s expression. Methods All 100 patients with acute cerebral infarction were randomLy divided into treatment group(conventional therapy + edaravone) and the control group(conventional treatment) 50 patients, and to compare the efficacy and MMP-9’s changes. Results The total effective rate of the treatment group was higher than the control group，two groups’ neurological deficit score were lower， and the treatment group were significantly lower than the control group，two groups’MMP-9 levels were significantly lower，and the treatment group was significantly lower than the control group(P<0.05). Conclusion Edaravone treatment of acute cerebral infarction can significantly reduce the level of MMP-9，and it is worthy of attention.
[Key words] Acute cerebral infarction；Edaravone；Matrix metalloproteinase 9(MMP-9)；Impact
急性脑梗死是由多因素、多机制、多环节所致的病理生理过程，研究发现，基质金属蛋白酶9(MMP-9)也参与了脑梗死的发病过程。依达拉奉是一种新型自由基清除剂，可以降低氧自由基的浓度，稳定神经细胞膜[1]。本文旨在探讨依达拉奉治疗急性脑梗死的疗效以及对急性脑梗死患者血清MMP-9的影响，现报道如下。
1资料与方法
1.1一般资料
选择2008年1月~2010年1月我院收治的100例急性脑梗死患者进行观察，其中男63例，女37例，年龄42~79岁，根据入院先后顺序随机分为治疗组和对照组各50例，两组患者的性别、年龄等临床资料比较差异无统计学意义(P>0.05)，具有可比性。
1.2治疗方法
两组患者均给予抗血小板聚集、脱水、扩容等脑梗死常规治疗；其中治疗组同时给予依达拉奉(南京先声东元制药有限公司，批号H20031342)30mg加入生理盐水100mL静滴 ......
您现在查看是摘要介绍页，详见PDF附件(1907KB，2页)。